|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Overexpression of the p53 protein correlated with cigarette smoking: 10 (56%) of the 18 adenocarcinomas from patients who were current smokers overexpressed p53 compared with 13 (33%) of the 40 adenocarcinomas from patients who had quit smoking and 0 (0%) of the 12 adenocarcinomas from patients who had never smoked (p = 0.002, trend test).
|
8434702 |
1993 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Alterations of the retinoblastoma (Rb) gene were evaluated in nine primary endometrial adenocarcinomas that we had previously analyzed for the presence of Ki-ras activations and p53 alterations and in three endometrial carcinoma cell lines.
|
8105795 |
1993 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Abnormalities of the tumour suppressor gene p53 have been shown in approximately 60% of advanced gastric adenocarcinomas and it has been suggested that the immunohistochemical finding of increased p53 expression is a prognostic marker in gastric cancer.
|
7829004 |
1994 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
To assess potential clinical applications for molecular genetic markers associated with human esophageal tumorigenesis, ten patients with primary esophageal adenocarcinomas were studied prospectively to evaluate expression of the p53 and H-ras genes.
|
8076380 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
APC and p53 mutations in de novo colorectal adenocarcinomas.
|
8081386 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Aneuploid cell populations from Barrett's adenocarcinomas have a high prevalence of 17p allelic losses, and there is substantial evidence that the target of these losses is the p53 gene.
|
8162566 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
This study was conducted to investigate the p53 gene alterations in 25 surgically-resected gastric adenocarcinomas in the Korea Cancer Center Hospital by polymerase chain reaction single-strand conformation polymorphism analysis (PCR-SSCP) for exons 4-8 and immunohistochemical staining (IHCS) with anti-p53 antibody, DO-7. p53 mutations were detected in nine (36%) out of 25 cancer tissues by PCR-SSCP in exon 4-8: 0,1,1,6 and 1 mutations in exons 4,5,6,7 and 8, respectively.
|
8067692 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Expression of the p53 protein was analyzed in 36 cases of carcinoma in adenoma in the colon by immunohistochemistry using an anti-human p53 monoclonal antibody (PAb1801).
|
8062281 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
In 3 patients, the same p53 mutations were found in both high-grade dysplasia and adenocarcinoma.All 14 patients had aneuploidy.
|
8194706 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Mutations in the p53 gene occurred more frequently in serous adenocarcinomas (14/31, 45%) than in all nonserous types of malignant epithelial tumors combined (7/34, 21%; P = 0.032).
|
7852189 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
In the samples positive for p53 protein, gene mutations in exons 5, 7 and 8 were detected by utilizing single-strand conformation polymorphism analysis (SSCP) in 1 Barrett's metaplasia specimen and 6 adenocarcinomas.
|
7906678 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The pattern of p53 mutations differed between isthmus and cervical adenocarcinomas: all of the mutations in the former were one-base substitutions of the transition type, whereas in the latter nearly half of the mutations were of the transversion type.
|
7960232 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Point mutations were localized to exons 5 and 7 of the p53 gene, previously recognized as "hot spots." p53 gene mutations and immunoreactivity were detected in 7 of 10 patients with primary esophageal adenocarcinomas and in 6 patients with associated Barrett's epithelium, 3 of whom had high-grade dysplasia.
|
8311140 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.
|
8020801 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
In the aneuploid lesions p53 immunoreactivity was not observed in mildly atypical adenomas, whereas 17% of the moderately atypical, 24% of the severely atypical adenomas and 66% of the adenocarcinomas were p53 positive.
|
8205349 |
1994 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
No significant correlation was observed between p53 protein expression and most of the clinico-pathological and flow-cytometric parameters (sex, age, tobacco smoking, chronic alcohol consumption, size of the tumor, grade of differentiation, depth of infiltration, presence of lymph node metastases, UICC stage, DNA-ploidy, S phase fraction). p53 protein expression was more frequent in Lauren's intestinal adenocarcinomas (67%) when compared to the diffuse type tumors (24%) (p = 0.002).
|
7540752 |
1994 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Cases of multiple synchronous adenomas showed different patterns of p53 expression but more positivity was found in adenomas from patients with a synchronous adenocarcinoma.
|
8076381 |
1994 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
The results suggest that overexpression of p53 protein is of marginal prognostic value in local prostatic adenocarcinomas, whereas direct measurement of cell proliferation by PCNA immunolabelling provides important prognostic information in T1-2M0 tumours, in addition to the Gleason score.
|
7913085 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
The statistical significance was maintained even when the comparison was restricted to strong p53 staining in moderately to poorly differentiated adenocarcinomas (P < 0.05).
|
7520348 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas.
|
8158699 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
In 41 primary adenocarcinomas, c-K-ras codon 12 point mutations were detected in 8 (19.5%) tumors and p53 point mutations were detected in 10 (24.4%) tumors, with one tumor harboring both mutations.
|
8311114 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Although the rate of p53 mutations in pancreatic tumours is of the same order as in other adenocarcinomas (> or = 50%), an antibody response was found in only 5/78 (6.4%) sera from patients with pancreatic cancer.
|
7947080 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
In 40 sporadic gastric adenocarcinomas, nine tumors (22.5%) with p53 mutations in exons 5-8, and six tumors (15%) with the USM+ phenotype, were detected.
|
8062274 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
CTD_mouse |
Overexpression of p53 protein, which is frequently demonstrated in virulent phenotypes of human corpus cancers, was seen in three out of eight (38%) adenocarcinomas, but not in the atypical hyperplasia or normal endometrial glands.
|
7955072 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We identified p53 mutations in 19 (70%) of 27 primary pancreatic adenocarcinomas.
|
8187092 |
1994 |